Literature DB >> 36119840

Brachyury promotes proliferation and migration of hepatocellular carcinoma via facilitating the transcription of NCAPG2.

Song Li1, Yijie Lu1, Yaopeng Xu1, Cong Zhang1, Biren Liu1, Ancheng Qin1, Zhiming Qiao1, Cong Shen2, Jun Shen3, Yuting Liang4, Jianwu Wu1, Xinwei Jiang1.   

Abstract

Hepatocellular carcinoma (HCC) has a poor prognosis because of its limited drug responses in clinical trials. Therefore, it is crucial to clarify the molecular mechanisms of HCC progression to identify new diagnostic markers and therapeutic targets. Here, we report that brachyury, which regulates the gene encoding the non-SMC condensin II complex subunit G2 (NCAPG2), promotes tumorigenesis in HCC. Knockdown of brachyury led to inhibition of cancer progression in vitro and in vivo. Chromatin immunoprecipitation-sequencing data indicated that the oncogene NCAPG2 is a direct target of brachyury. Furthermore, NCAPG2 knockdown inhibited the proliferation and migration of HCC cells and attenuated brachyury-induced tumorigenesis. Overexpression and decreased DNA methylation of NCAPG2 were associated with a poor prognosis, and NCAPG2 was positively correlated with various immune cell infiltrates, cancer-associated fibroblasts, and immune checkpoint molecule expression levels in the tumor microenvironment. Moreover, the effectiveness of immune checkpoint blockade was decreased in the high NCAPG2 expression group. Together, these findings demonstrated a coregulatory effect of the brachyury/NCAPG2 axis during HCC progression. AJCR
Copyright © 2022.

Entities:  

Keywords:  Hepatocellular carcinoma; NCAPG2; brachyury; tumor microenvironment; tumorigenesis

Year:  2022        PMID: 36119840      PMCID: PMC9442014     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  45 in total

1.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.

Authors:  Tathiane M Malta; Artem Sokolov; Andrew J Gentles; Tomasz Burzykowski; Laila Poisson; John N Weinstein; Bożena Kamińska; Joerg Huelsken; Larsson Omberg; Olivier Gevaert; Antonio Colaprico; Patrycja Czerwińska; Sylwia Mazurek; Lopa Mishra; Holger Heyn; Alex Krasnitz; Andrew K Godwin; Alexander J Lazar; Joshua M Stuart; Katherine A Hoadley; Peter W Laird; Houtan Noushmehr; Maciej Wiznerowicz
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

2.  It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade.

Authors:  Tsung-Hao Liu; Yu-Yun Shao; Chih-Hung Hsu
Journal:  J Formos Med Assoc       Date:  2020-07-11       Impact factor: 3.282

3.  T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines.

Authors:  Su Chen; Jian Jiao; Dongjie Jiang; Zongmiao Wan; Lei Li; Ke Li; Leqin Xu; Zhenhua Zhou; Wei Xu; Jianru Xiao
Journal:  Tumour Biol       Date:  2015-03-06

4.  microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2.

Authors:  Hai-Tao Dai; Shu-Tong Wang; Bin Chen; Ke-Yu Tang; Nan Li; Chun-Yong Wen; Yuan Wan; Gui-Yuan Zhang; Yong-Hui Huang; Zhi-Jun Geng
Journal:  Neoplasma       Date:  2021-11-25       Impact factor: 2.575

5.  T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.

Authors:  Filipe Pinto; Nelma Pértega-Gomes; Márcia S Pereira; José R Vizcaíno; Pedro Monteiro; Rui M Henrique; Fátima Baltazar; Raquel P Andrade; Rui M Reis
Journal:  Clin Cancer Res       Date:  2014-07-09       Impact factor: 12.531

6.  The Immune Landscape of Cancer.

Authors:  Vésteinn Thorsson; David L Gibbs; Scott D Brown; Denise Wolf; Dante S Bortone; Tai-Hsien Ou Yang; Eduard Porta-Pardo; Galen F Gao; Christopher L Plaisier; James A Eddy; Elad Ziv; Aedin C Culhane; Evan O Paull; I K Ashok Sivakumar; Andrew J Gentles; Raunaq Malhotra; Farshad Farshidfar; Antonio Colaprico; Joel S Parker; Lisle E Mose; Nam Sy Vo; Jianfang Liu; Yuexin Liu; Janet Rader; Varsha Dhankani; Sheila M Reynolds; Reanne Bowlby; Andrea Califano; Andrew D Cherniack; Dimitris Anastassiou; Davide Bedognetti; Younes Mokrab; Aaron M Newman; Arvind Rao; Ken Chen; Alexander Krasnitz; Hai Hu; Tathiane M Malta; Houtan Noushmehr; Chandra Sekhar Pedamallu; Susan Bullman; Akinyemi I Ojesina; Andrew Lamb; Wanding Zhou; Hui Shen; Toni K Choueiri; John N Weinstein; Justin Guinney; Joel Saltz; Robert A Holt; Charles S Rabkin; Alexander J Lazar; Jonathan S Serody; Elizabeth G Demicco; Mary L Disis; Benjamin G Vincent; Ilya Shmulevich
Journal:  Immunity       Date:  2018-04-05       Impact factor: 43.474

7.  The Role of Transcriptional Factor Brachyury on Cell Cycle Regulation in Non-small Cell Lung Cancer.

Authors:  Jingyi Xu; Ming Chen; Yinghui Wu; Hong Zhang; Jundong Zhou; Donglai Wang; Tianming Zou; Jun Shen
Journal:  Front Oncol       Date:  2020-07-03       Impact factor: 6.244

8.  BMI1 promotes steroidogenesis through maintaining redox homeostasis in mouse MLTC-1 and primary Leydig cells.

Authors:  Tingting Gao; Meng Lin; Binbin Shao; Qiao Zhou; Yufeng Wang; Xia Chen; Dan Zhao; Xiuliang Dai; Cong Shen; Hongbo Cheng; Shenmin Yang; Hong Li; Bo Zheng; Xingming Zhong; Jun Yu; Li Chen; Xiaoyan Huang
Journal:  Cell Cycle       Date:  2020-06-28       Impact factor: 4.534

9.  BMI1 Drives Steroidogenesis Through Epigenetically Repressing the p38 MAPK Pathway.

Authors:  Jun Yu; Yibo Wu; Hong Li; Hui Zhou; Cong Shen; Tingting Gao; Meng Lin; Xiuliang Dai; Jian Ou; Meiling Liu; Xiaoyan Huang; Bo Zheng; Fei Sun
Journal:  Front Cell Dev Biol       Date:  2021-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.